Related Experiment Videos
Summary
Cefoperazone shows higher biliary excretion than cephazolin in animals and humans. This antibiotic is effective for biliary tract infections due to its broad spectrum and bile penetration.
Area of Science:
- Pharmacology
- Microbiology
- Hepatology
Background:
- Investigating the biliary excretion of cefoperazone compared to cephazolin.
- Assessing cefoperazone's efficacy and safety in treating biliary tract infections.
Observation:
- Cefoperazone exhibited significantly higher biliary excretion than cephazolin across multiple animal species (rats, rabbits, dogs, monkeys).
- Experimentally induced liver cirrhosis in rats markedly reduced cefoperazone's biliary excretion.
- Human studies confirmed higher biliary excretion of cefoperazone compared to cephazolin.
Findings:
- Cefoperazone demonstrated high efficacy in 78% of patients with biliary tract infections (cholecystitis, cholangitis, liver abscess).
- The incidence of adverse effects associated with cefoperazone treatment was low.
- High cefoperazone penetration into bile was observed.
Implications:
- Cefoperazone's favorable biliary excretion profile and broad antibacterial spectrum support its use in treating biliary tract infections.
- The findings suggest cefoperazone as a valuable therapeutic option for infections involving the biliary system.
- Further research could explore cefoperazone's role in specific biliary pathologies and its pharmacokinetics in patients with varying degrees of liver dysfunction.